AKT1 and breast carcinoma: Tier I/II mutations were detected in 481 (36%) of all breast cancer samples, the majority of which (279/58%) having ≥1 mutation in the PI3K/AKT pathway (PIK3CA, AKT1, and PTEN) (20% total cohort frequency).